{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:19:21Z","timestamp":1768295961491,"version":"3.49.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0013243","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000}}],"reference-count":153,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are several known pathogens and families identified as high risk for pandemic potential. It is essential to study these pathogens and develop medical countermeasures to mitigate disease prior to potential pandemics. Controlled human infection models (CHIMs) using attenuated viral strains may offer an efficient and safe way to do this.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our aim was to systematically examine the literature for attenuated, but replication competent, strains of Coalition for Epidemic Preparedness Innovations (CEPI) identified priority pathogens (Ebola, Lassa virus, Nipah virus, Rift Valley fever virus, chikungunya virus and Middle East respiratory syndrome-related coronavirus) that have been administered to humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A comprehensive literature search of multiple databases was performed by an information specialist. All search results were screened by two authors against inclusion\/exclusion criteria from a pre-specified protocol. The primary outcome was confirmation that the administered viral strain could subsequently be recovered from participants. The secondary outcome was attenuated virus safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our searches yielded 13078 results and 5998 articles remained for screening after removing duplicates and animal studies. Subsequently, 351 articles were selected for full text review and nine were included for data extraction. Four distinct attenuated strains were identified across two priority pathogens \u2013 TSI-GSD-218 and VLA1553 for chikungunya virus and MP-12 and hRVFV-4s for Rift Valley Fever virus. Attenuated virus was recovered for each strain except hRVFV-4s. There were no major safety concerns for these identified strains in Phase 1\u20133 studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We have identified three attenuated viral strains that may be amenable to development into novel CHIMs for two priority pathogens. Of these, VLA1553 for chikungunya is a licenced and commercially available vaccine product suitable for use in CHIM. There is a research gap for the creation of new attenuated mutants that could be utilised in CHIM for other priority pathogens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0013243","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T19:02:13Z","timestamp":1767380533000},"page":"e0013243","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-5030","authenticated-orcid":true,"given":"David Oliver","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilly","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Lutje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela M.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"4","key":"pntd.0013243.ref001","first-page":"463","article-title":"Updated WHO list of emerging pathogens for a potential future pandemic: Implications for public health and global preparedness","volume":"32","author":"BM Ukoaka","year":"2024","journal-title":"Infez Med"},{"issue":"2","key":"pntd.0013243.ref002","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70227","article-title":"Unveiling the Threat of Disease X: Preparing for the Next Global Pandemic","volume":"97","author":"M Zhao","year":"2025","journal-title":"J Med Virol"},{"key":"pntd.0013243.ref003","unstructured":"Gouglas D, Christodoulou M, Hatchett R. The 100 Days Mission\u20142022 Global Pandemic Preparedness Summit. LID - e221142 FAU - Gouglas, Dimitrios. (1080-6040 (Print))."},{"issue":"11","key":"pntd.0013243.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(24)00286-9","article-title":"Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study","volume":"12","author":"G Barnsley","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"1","key":"pntd.0013243.ref005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/epirev\/mxz012","article-title":"CEPI: Driving Progress Toward Epidemic Preparedness and Response","volume":"41","author":"D Gouglas","year":"2019","journal-title":"Epidemiol Rev"},{"key":"pntd.0013243.ref006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","article-title":"The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts","volume":"159","author":"MS Mehand","year":"2018","journal-title":"Antiviral Res"},{"key":"pntd.0013243.ref007","doi-asserted-by":"crossref","first-page":"102676","DOI":"10.1016\/j.tmaid.2023.102676","article-title":"Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization\u2019s Blueprint forAction toPreventEpidemics","volume":"57","author":"J Salmanton-Garc\u00eda","year":"2024","journal-title":"Travel Med Infect Dis"},{"key":"pntd.0013243.ref008","article-title":"Coalition for Epidemic Preparedness Innovations: Priority Pathogens.","author":"Coalition for Epidemic Preparedness Innovations"},{"issue":"7830","key":"pntd.0013243.ref009","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"KS Corbett","year":"2020","journal-title":"Nature"},{"issue":"7830","key":"pntd.0013243.ref010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"F Krammer","year":"2020","journal-title":"Nature"},{"key":"pntd.0013243.ref011","author":"MusiCC"},{"issue":"12","key":"pntd.0013243.ref012","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(12)70292-X","article-title":"Human microbial challenge: the ultimate animal model","volume":"12","author":"AJ Pollard","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pntd.0013243.ref013","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.vaccine.2016.08.086","article-title":"Controlled human infection with RSV: The opportunities of experimental challenge","volume":"35","author":"MS Habibi","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"pntd.0013243.ref014","article-title":"Controlled human infection models to accelerate vaccine development","volume":"35","author":"RKM Choy","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"pntd.0013243.ref015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/cid\/ciac820","article-title":"A Systematic Review of Human Challenge Trials, Designs, and Safety","volume":"76","author":"J Adams-Phipps","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6493","key":"pntd.0013243.ref016","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1126\/science.abc1076","article-title":"Ethics of controlled human infection to address COVID-19","volume":"368","author":"SK Shah","year":"2020","journal-title":"Science"},{"issue":"10","key":"pntd.0013243.ref017","first-page":"638","article-title":"Vaxchora: The First FDA-Approved Cholera Vaccination in the United States","volume":"42","author":"JF Mosley","year":"2017","journal-title":"P T"},{"issue":"3","key":"pntd.0013243.ref018","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1473-3099(18)30087-2","article-title":"Typhoid conjugate vaccine gets WHO prequalification","volume":"18","author":"T Burki","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10111","key":"pntd.0013243.ref019","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"C Jin","year":"2017","journal-title":"Lancet"},{"key":"pntd.0013243.ref020","unstructured":"World Health Organisation. Human challenge trials for vaccine development: regulatory considerations, Annex 10, TRS No 1004. 2017."},{"key":"pntd.0013243.ref021","author":"World Health Organisation"},{"key":"pntd.0013243.ref022","author":"BMJ Williams","year":"2023"},{"key":"pntd.0013243.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.07.069","article-title":"Vaccine value profile for Chikungunya","volume":"42","author":"X Flandes","year":"2024","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0013243.ref024","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/fmb.12.15","article-title":"Human challenge studies: a review of adequacy of reporting methods and results","volume":"7","author":"JA Kalil","year":"2012","journal-title":"Future Microbiol"},{"issue":"330","key":"pntd.0013243.ref025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"BD Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"key":"pntd.0013243.ref026","article-title":"Low-dose dengue virus 3 human challenge model: a phase 1 open-label study","author":"AT Waickman","year":"2024","journal-title":"Nat Microbiol"},{"key":"pntd.0013243.ref027","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12688\/wellcomeopenres.18767.2","article-title":"Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi","volume":"8","author":"SB Gordon","year":"2023","journal-title":"Wellcome Open Res"},{"issue":"12","key":"pntd.0013243.ref028","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41590-018-0231-y","article-title":"Inflammation induced by influenza virus impairs human innate immune control of pneumococcus","volume":"19","author":"SP Jochems","year":"2018","journal-title":"Nat Immunol"},{"key":"pntd.0013243.ref029","author":"ELC Aromataris"},{"issue":"7","key":"pntd.0013243.ref030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"pntd.0013243.ref031","doi-asserted-by":"crossref","first-page":"1211388","DOI":"10.3389\/fimmu.2023.1211388","article-title":"Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges","volume":"14","author":"H Morrison","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"pntd.0013243.ref032","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"B Killingley","year":"2022","journal-title":"Nat Med"},{"issue":"8019","key":"pntd.0013243.ref033","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-024-07575-x","article-title":"Human SARS-CoV-2 challenge uncovers local and systemic response dynamics","volume":"631","author":"RGH Lindeboom","year":"2024","journal-title":"Nature"},{"issue":"11","key":"pntd.0013243.ref034","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/cid\/ciaa1290","article-title":"Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers","volume":"72","author":"MM Levine","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pntd.0013243.ref035","article-title":"Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022","volume":"3","author":"HIC-Vac meeting contributors","year":"2023","journal-title":"Immunother Adv"},{"issue":"10","key":"pntd.0013243.ref036","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2020076","article-title":"Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models","volume":"383","author":"ME Deming","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pntd.0013243.ref037","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"M Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"pntd.0013243.ref038","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JPT Higgins","year":"2011","journal-title":"BMJ"},{"key":"pntd.0013243.ref039","doi-asserted-by":"crossref","first-page":"108602","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"JPT Higgins","year":"2024","journal-title":"Environ Int"},{"issue":"3","key":"pntd.0013243.ref040","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/514240","article-title":"Immunologic interference from sequential administration of live attenuated alphavirus vaccines","volume":"177","author":"DJ McClain","year":"1998","journal-title":"J Infect Dis"},{"issue":"6","key":"pntd.0013243.ref041","first-page":"681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"1","author":"R Edelman","year":"2000","journal-title":"Journal of Infectious Diseases"},{"issue":"10394","key":"pntd.0013243.ref042","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"M Schneider","year":"2023","journal-title":"Lancet"},{"key":"pntd.0013243.ref043","doi-asserted-by":"crossref","unstructured":"McMahon R, Fuchs U, Schneider M, Hadl S, Hochreiter R, Bitzer A. A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults. 2024;1(2).","DOI":"10.1093\/jtm\/taad156"},{"issue":"11","key":"pntd.0013243.ref044","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S1473-3099(24)00375-X","article-title":"Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial","volume":"24","author":"I Leroux-Roels","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pntd.0013243.ref045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","volume":"34","author":"PR Pittman","year":"2016","journal-title":"Vaccine"},{"issue":"10","key":"pntd.0013243.ref046","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial","volume":"1","author":"N Wressnigg","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"issue":"4","key":"pntd.0013243.ref047","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"PR Pittman","year":"2016","journal-title":"Vaccine"},{"key":"pntd.0013243.ref048","doi-asserted-by":"crossref","unstructured":"Hoke CH, Pace-Templeton J, Pittman P, Malinoski FJ, Gibbs P, Ulderich T. US Military contributions to the global response to pandemic chikungunya. 2012;1(47):6713\u201320.","DOI":"10.1016\/j.vaccine.2012.08.025"},{"issue":"1","key":"pntd.0013243.ref049","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41541-024-01012-w","article-title":"A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs","volume":"9","author":"BD Carey","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"2","key":"pntd.0013243.ref050","first-page":"24","article-title":"A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region","volume":"11","author":"Y Cai","year":"2020","journal-title":"mBio"},{"key":"pntd.0013243.ref051","unstructured":"Japan Registry of Clinical Trials. Evaluation of efficacy and safety of Ebola vaccine iEvac-Z in human. In: Kawaoka Yoshihiro Approval 01\/01\/ ethics@m.u-tokyo.ac.jp The University of Tokyo CRRBemu-taj, editor. 2019."},{"issue":"5","key":"pntd.0013243.ref052","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00650-13","article-title":"Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate","volume":"4","author":"F Almaz\u00e1n","year":"2013","journal-title":"mBio"},{"issue":"2","key":"pntd.0013243.ref053","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00103-21","article-title":"Genetically engineered live-attenuated Middle East respiratory syndrome coronavirus viruses confer full protection against lethal infection","volume":"12","author":"J Guti\u00e9rrez-\u00c1lvarez","year":"2021","journal-title":"mBio"},{"issue":"6","key":"pntd.0013243.ref054","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00346-17","article-title":"Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis","volume":"2","author":"VD Menachery","year":"2017","journal-title":"mSphere"},{"issue":"40","key":"pntd.0013243.ref055","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1073\/pnas.1311542110","article-title":"Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus","volume":"110","author":"T Scobey","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pntd.0013243.ref056","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41467-023-36754-z","article-title":"Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase","volume":"14","author":"SK Myeni","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"pntd.0013243.ref057","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00203-024-04120-2","article-title":"Cold-adapted live attenuated MERS-CoV vaccine strain remains attenuated in mice after multiple passages in Vero cells at 37 \u00b0C","volume":"206","author":"H Seo","year":"2024","journal-title":"Arch Microbiol"},{"key":"pntd.0013243.ref058","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1038\/ncomms8483","article-title":"The immunomodulating V and W proteins of Nipah virus determine disease course","volume":"6","author":"BA Satterfield","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"pntd.0013243.ref059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012709","article-title":"The nonstructural proteins of Nipah virus play a key role in pathogenicity in experimentally infected animals","volume":"5","author":"M Yoneda","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"pntd.0013243.ref060","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/517537","article-title":"Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients","volume":"44","author":"G Borgherini","year":"2007","journal-title":"Clin Infect Dis"},{"key":"pntd.0013243.ref061","first-page":"101003","article-title":"High-resolution spatiotemporal analysis of chikungunya epidemics between 2019 and 2020 in Salvador, Brazil: a municipality-level transmission dynamics study","volume":"43","author":"HD Argibay","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"pntd.0013243.ref062","author":"World Health Organisation","year":"2025"},{"issue":"3","key":"pntd.0013243.ref063","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"LA Silva","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"pntd.0013243.ref064","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/pathogens14010063","article-title":"Introduction of Vector-Borne Infections in Europe: Emerging and Re-Emerging Viral Pathogens with Potential Impact on One Health","volume":"14","author":"J Logiudice","year":"2025","journal-title":"Pathogens"},{"issue":"12","key":"pntd.0013243.ref065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-016648","article-title":"The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease","volume":"9","author":"AM de Roo","year":"2024","journal-title":"BMJ Glob Health"},{"issue":"12","key":"pntd.0013243.ref066","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(24)00357-8","article-title":"Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study","volume":"24","author":"R McMahon","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pntd.0013243.ref067","article-title":"From bench to clinic: the development of VLA1553\/IXCHIQ, a live-attenuated chikungunya vaccine","volume":"31","author":"LH Chen","year":"2024","journal-title":"J Travel Med"},{"key":"pntd.0013243.ref068","unstructured":"Richardson JS, Anderson D, Mendy J, Muhammad S, Tindale L, Loreth T, et al. 2888. Safety and Immunogenicity of an Adjuvanted Chikungunya Virus (CHIKV) Virus-like Particle (VLP) Based Vaccine in Two Pivotal Phase 3 Trials, \u226512 Years of Age. LID - ofad500.2471. (2328-8957 (Electronic))."},{"key":"pntd.0013243.ref069","author":"Contagion Editorial Team","year":"2025"},{"issue":"6","key":"pntd.0013243.ref070","article-title":"Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate","volume":"11","author":"Y-H Chan","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"12","key":"pntd.0013243.ref071","first-page":"6748","article-title":"Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL\/6J mice","volume":"1","author":"A Piper","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"pntd.0013243.ref072","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002719","article-title":"Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design","volume":"1","author":"CL Gardner","year":"2014","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"18","key":"pntd.0013243.ref073","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00775-19","article-title":"Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated In Vivo and Have Compromised Transmissibility","volume":"93","author":"L Carrau","year":"2019","journal-title":"J Virol"},{"issue":"1","key":"pntd.0013243.ref074","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/vaccines7010002","article-title":"Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate","volume":"7","author":"E Abeyratne","year":"2018","journal-title":"Vaccines (Basel)"},{"issue":"15","key":"pntd.0013243.ref075","article-title":"Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine","volume":"93","author":"Y-N Zhang","year":"2019","journal-title":"J Virol"},{"issue":"11","key":"pntd.0013243.ref076","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3390\/vaccines10111939","article-title":"Generation of a Live-Attenuated Strain of Chikungunya Virus from an Indian Isolate for Vaccine Development","volume":"10","author":"SR Nair","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"pntd.0013243.ref077","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004007","article-title":"Extended preclinical safety, efficacy and stability testing of a live-attenuated chikungunya vaccine candidate","volume":"1","author":"KS Plante","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0013243.ref078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012120","article-title":"Live-attenuated CHIKV vaccine with rearranged genome replicates in vitro and induces immune response in mice","volume":"18","author":"I Tretyakova","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0013243.ref079","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/v17020281","article-title":"Attenuation of Chikungunya Virus by a Single Amino Acid Substitution in the nsP1 Component of a Non-Structural Polyprotein","volume":"17","author":"J Chamberlain","year":"2025","journal-title":"Viruses"},{"issue":"5","key":"pntd.0013243.ref080","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JVI.03453-13","article-title":"Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice","volume":"88","author":"D Halleng\u00e4rd","year":"2014","journal-title":"J Virol"},{"issue":"6","key":"pntd.0013243.ref081","article-title":"Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus","volume":"1","author":"P Roques","year":"2017","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"pntd.0013243.ref082","author":"Medicines and Healthcare products Regulatory Agency","year":"2025"},{"issue":"6","key":"pntd.0013243.ref083","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40259-024-00677-y","article-title":"Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure","volume":"38","author":"WC Weber","year":"2024","journal-title":"BioDrugs"},{"issue":"10","key":"pntd.0013243.ref084","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(25)00552-3","article-title":"More data needed on the FDA\u2019s decision to suspend Ixchiq","volume":"25","author":"The Lancet Infectious Diseases","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"pntd.0013243.ref085","author":"Food and Drug Administration","year":"2025"},{"issue":"9","key":"pntd.0013243.ref086","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf550","article-title":"Fatal adverse event after VLA1553 chikungunya vaccination in an elderly patient: a case report from Reunion Island","volume":"12","author":"E Mosnier","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"pntd.0013243.ref087","first-page":"157","article-title":"Development of an attenuated strain of chikungunya virus for use in vaccine production","volume":"1","author":"NH Levitt","year":"1986","journal-title":"Journal Title Abbreviation"},{"issue":"11","key":"pntd.0013243.ref088","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","article-title":"Attenuation of Chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein","volume":"86","author":"R Gorchakov","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"pntd.0013243.ref089","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41541-023-00769-w","article-title":"Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates","volume":"8","author":"C Alkan","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"8","key":"pntd.0013243.ref090","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1099\/jgv.0.001296","article-title":"Rift Valley fever: biology and epidemiology","volume":"100","author":"D Wright","year":"2019","journal-title":"J Gen Virol"},{"issue":"8","key":"pntd.0013243.ref091","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002694","article-title":"Rift valley fever: diagnostic challenges and investment needs for vaccine development","volume":"5","author":"V Petrova","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"6","key":"pntd.0013243.ref092","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"T Ikegami","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"pntd.0013243.ref093","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010233","article-title":"Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis","volume":"16","author":"Z Anywaine","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013243.ref094","first-page":"1","article-title":"Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine","volume":"30","author":"KC Smithburn","year":"1949","journal-title":"Br J Exp Pathol"},{"issue":"1","key":"pntd.0013243.ref095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/vim.2022.0104","article-title":"Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome","volume":"36","author":"VB Ayers","year":"2023","journal-title":"Viral Immunol"},{"issue":"39","key":"pntd.0013243.ref096","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1016\/j.vaccine.2014.07.037","article-title":"Comparative efficacy of two next-generation Rift Valley fever vaccines","volume":"32","author":"J Kortekaas","year":"2014","journal-title":"Vaccine"},{"key":"pntd.0013243.ref097","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-4939-3387-7_9","article-title":"Generation of a Single-Cycle Replicable Rift Valley Fever Vaccine","volume":"1403","author":"S Murakami","year":"2016","journal-title":"Methods Mol Biol"},{"key":"pntd.0013243.ref098","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1016\/j.vaccine.2017.10.036","article-title":"Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain","volume":"35","author":"HJ Ly","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0013243.ref099","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"R Muller","year":"1995","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"pntd.0013243.ref100","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.vaccine.2022.12.056","article-title":"Rift Valley Fever vaccine strategies: Enhanced stability of RVF Clone 13","volume":"41","author":"B Moetlhoa","year":"2023","journal-title":"Vaccine"},{"issue":"11","key":"pntd.0013243.ref101","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/vaccines10111794","article-title":"An Overview of Rift Valley Fever Vaccine Development Strategies","volume":"10","author":"PK Kitandwe","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"pntd.0013243.ref102","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.jvacx.2020.100060","article-title":"Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile","volume":"5","author":"TP Monath","year":"2020","journal-title":"Vaccine X"},{"issue":"24","key":"pntd.0013243.ref103","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"BH Bird","year":"2011","journal-title":"J Virol"},{"issue":"8","key":"pntd.0013243.ref104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012011","article-title":"The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation","volume":"18","author":"B Borrego","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0013243.ref105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/v16070999","article-title":"Distinct Pathological Changes in Preweaning Mice Infected with Live-Attenuated Rift Valley Fever Virus Strains","volume":"16","author":"C Alkan","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"pntd.0013243.ref106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41541-022-00536-3","article-title":"Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models","volume":"7","author":"T Ikegami","year":"2022","journal-title":"NPJ Vaccines"},{"key":"pntd.0013243.ref107","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","author":"H Caplen","year":"1985","journal-title":"J Gen Virol"},{"issue":"1","key":"pntd.0013243.ref108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"JC Morrill","year":"1991","journal-title":"Vaccine"},{"issue":"7","key":"pntd.0013243.ref109","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"JC Morrill","year":"1987","journal-title":"Am J Vet Res"},{"issue":"1","key":"pntd.0013243.ref110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2460\/ajvr.1991.52.01.50","article-title":"Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever","volume":"52","author":"KA Hubbard","year":"1991","journal-title":"Am J Vet Res"},{"issue":"3","key":"pntd.0013243.ref111","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0034-5288(92)90029-2","article-title":"Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine","volume":"52","author":"A Baskerville","year":"1992","journal-title":"Res Vet Sci"},{"key":"pntd.0013243.ref112","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/S0264-410X(03)00131-2","article-title":"Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys","volume":"21","author":"JC Morrill","year":"2003","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0013243.ref113","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/infdis\/jir354","article-title":"Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine","volume":"204","author":"JC Morrill","year":"2011","journal-title":"J Infect Dis"},{"issue":"12","key":"pntd.0013243.ref114","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever","volume":"19","author":"T Ikegami","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"18","key":"pntd.0013243.ref115","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1128\/JVI.00961-14","article-title":"Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging","volume":"88","author":"PJ Wichgers Schreur","year":"2014","journal-title":"J Virol"},{"issue":"1","key":"pntd.0013243.ref116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41541-020-00212-4","article-title":"Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle","volume":"5","author":"PJ Wichgers Schreur","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pntd.0013243.ref117","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-022-00476-y","article-title":"Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset","volume":"7","author":"PJ Wichgers Schreur","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"4","key":"pntd.0013243.ref118","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1073\/pnas.0708057105","article-title":"Generation of biologically contained Ebola viruses","volume":"105","author":"P Halfmann","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pntd.0013243.ref119","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"ST Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"pntd.0013243.ref120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: A snapshot","volume":"17","author":"C Woolsey","year":"2021","journal-title":"PLoS Pathog"},{"issue":"10068","key":"pntd.0013243.ref121","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"AM Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"pntd.0013243.ref122","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41541-024-00985-y","article-title":"Filovirus vaccines as a response paradigm for emerging infectious diseases","volume":"9","author":"A Marzi","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"3","key":"pntd.0013243.ref123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012038","article-title":"Recent advances in the treatment of Ebola disease: A brief overview","volume":"20","author":"LW El Ayoubi","year":"2024","journal-title":"PLoS Pathog"},{"issue":"4","key":"pntd.0013243.ref124","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jcpa.2001.0503","article-title":"Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus","volume":"125","author":"M Bray","year":"2001","journal-title":"J Comp Pathol"},{"issue":"6","key":"pntd.0013243.ref125","first-page":"257","article-title":"Attempts to develop a vaccine against Ebola fever","volume":"40","author":"AA Chupurnov","year":"1995","journal-title":"Vopr Virusol"},{"issue":"8","key":"pntd.0013243.ref126","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/JVI.00074-09","article-title":"Replication-deficient ebolavirus as a vaccine candidate","volume":"83","author":"P Halfmann","year":"2009","journal-title":"J Virol"},{"key":"pntd.0013243.ref127","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiad240","article-title":"The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets","volume":"228","author":"PJ Halfmann","year":"2023","journal-title":"J Infect Dis"},{"issue":"10","key":"pntd.0013243.ref128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008900","article-title":"HER2-mediated enhancement of Ebola virus entry","volume":"16","author":"M Kuroda","year":"2020","journal-title":"PLoS Pathog"},{"issue":"6233","key":"pntd.0013243.ref129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates","volume":"348","author":"A Marzi","year":"2015","journal-title":"Science"},{"key":"pntd.0013243.ref130","volume-title":"2024 International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim; 5th March 2024","author":"T Watanabe"},{"key":"pntd.0013243.ref131","author":"K Cham"},{"issue":"1","key":"pntd.0013243.ref132","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","article-title":"Current perspectives on vaccines and therapeutics for Lassa Fever","volume":"21","author":"BM Warner","year":"2024","journal-title":"Virol J"},{"issue":"11","key":"pntd.0013243.ref133","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"IS Lukashevich","year":"2012","journal-title":"Viruses"},{"issue":"6","key":"pntd.0013243.ref134","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4161\/hv.7.6.15198","article-title":"Argentine hemorrhagic fever vaccines","volume":"7","author":"A Ambrosio","year":"2011","journal-title":"Hum Vaccin"},{"issue":"9","key":"pntd.0013243.ref135","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14760584.2016.1184575","article-title":"Vaccine platforms to control Lassa fever","volume":"15","author":"IS Lukashevich","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"41","key":"pntd.0013243.ref136","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"IS Lukashevich","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"pntd.0013243.ref137","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-virology-021920-113833","article-title":"Vaccines to Emerging Viruses: Nipah and Hendra","volume":"7","author":"M Amaya","year":"2020","journal-title":"Annu Rev Virol"},{"issue":"1","key":"pntd.0013243.ref138","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00400-X","article-title":"Medical countermeasures against henipaviruses: a review and public health perspective","volume":"22","author":"R G\u00f3mez Rom\u00e1n","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"pntd.0013243.ref139","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.5455\/OVJ.2023.v13.i9.1","article-title":"Advancing the frontiers: Revolutionary control and prevention paradigms against Nipah virus","volume":"13","author":"FL Orosco","year":"2023","journal-title":"Open Vet J"},{"issue":"1","key":"pntd.0013243.ref140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/v11010074","article-title":"Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism","volume":"11","author":"C Schindewolf","year":"2019","journal-title":"Viruses"},{"issue":"2","key":"pntd.0013243.ref141","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3201\/eid2602.190697","article-title":"Middle East Respiratory Syndrome Coronavirus Transmission","volume":"26","author":"ME Killerby","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"pntd.0013243.ref142","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: from SARS and MERS to COVID-19","volume":"27","author":"Y-D Li","year":"2020","journal-title":"J Biomed Sci"},{"key":"pntd.0013243.ref143","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus","volume":"10","author":"CY Yong","year":"2019","journal-title":"Front Microbiol"},{"issue":"8","key":"pntd.0013243.ref144","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae133","article-title":"Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine\u2020","volume":"31","author":"G Maurer","year":"2024","journal-title":"J Travel Med"},{"issue":"6","key":"pntd.0013243.ref145","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/vaccines13060576","article-title":"Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ\u00ae)","volume":"13","author":"G Maurer","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"pntd.0013243.ref146","doi-asserted-by":"crossref","first-page":"2469653","DOI":"10.1080\/22221751.2025.2469653","article-title":"Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages","volume":"14","author":"K Kosulin","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"pntd.0013243.ref147","doi-asserted-by":"crossref","first-page":"100565","DOI":"10.1016\/j.onehlt.2023.100565","article-title":"Novel approaches for the rapid development of rationally designed arbovirus vaccines","volume":"16","author":"JWM van Bree","year":"2023","journal-title":"One Health"},{"issue":"3","key":"pntd.0013243.ref148","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173328","article-title":"TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies","volume":"134","author":"KK Pierce","year":"2024","journal-title":"J Clin Invest"},{"issue":"11","key":"pntd.0013243.ref149","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1473-3099(24)00376-1","article-title":"Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil","volume":"24","author":"ML Nogueira","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"pntd.0013243.ref150","doi-asserted-by":"crossref","unstructured":"Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE, Streblow DN. Animal Models of Chikungunya Virus Infection and Disease. [Review]. 2016;1(suppl 5):S482\u2013s7.","DOI":"10.1093\/infdis\/jiw284"},{"issue":"9","key":"pntd.0013243.ref151","doi-asserted-by":"crossref","first-page":"100874","DOI":"10.1016\/S2666-5247(24)00097-1","article-title":"Harmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines?","volume":"5","author":"SA Baylis","year":"2024","journal-title":"Lancet Microbe"},{"issue":"4","key":"pntd.0013243.ref152","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.vaccine.2020.10.075","article-title":"Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group","volume":"39","author":"E Jamrozik","year":"2021","journal-title":"Vaccine"},{"key":"pntd.0013243.ref153","unstructured":"Impact Global Health. Landscape of Emerging Infectious Disease Research And Development: Lessons Learned. 2024."}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0013243","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:49:03Z","timestamp":1768243743000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013243"}},"subtitle":[],"editor":[{"given":"Gregory","family":"Gromowski","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013243","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}